Alphamab and Pfizer Initiate P-II Trial Evaluating KN046 + Inlyta (axitinib) as a 1L Treatment of Non-Small Cell Lung Cancer
Shots: The P-II trial will evaluate the efficacy, safety, and tolerability of KN046 + Pfizer’s Inlyta (axitinib) as a 1L treatment of NSCLC. The 1EPs of the study are ORR The P-II trial of KN046 for advanced NSCLC has demonstrated superior tolerability, safety, as well as PFS and OS. Following the results, the companies have […]